Denali Therapeutics Inc. (DNLI) stock
Close on Nov 11, 2026Market cap $3.15BP/E –Yield –
Denali Therapeutics Inc. reported revenue of $0 for fiscal 2025. Free cash flow was -$437.46M. At the latest close the market valued the company at $3.15B.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $3.15B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.78
- Dividend yield
- –
- Free cash flow yield
- -13.87%
Fundamentals
- Revenue
- $0
- Net income
- -$511.45M
- EPS, diluted
- -$2.84
- Free cash flow
- -$437.46M
- Book value per share
- $4.46
- Diluted shares
- 187M
Trading
- Next earnings
- Feb 25, 2027 (estimated, during market hours)
- Previous close
- $19.85
- Open
- $19.91
- Day's range
- $19.63 – $20.24
- Volume
- 873,559
- Average volume (20 days)
- 1,690,836
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.68
- 52-week range
- $15.18 – $27.30
- RSI (14 days)
- 50.9
- Volatility (1 year)
- 55.3%
- Relative volume
- 0.53×
- WACC
- 13.3%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | DNLI | S&P 500 | Difference | DNLI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +1.4% | -2.4% | +3.8 pts | ||
| 3 months | -20.1% | -1.2% | −18.9 pts | ||
| Year to date | +19.5% | +12.3% | +7.2 pts | ||
| 1 year | +12.2% | +12.4% | −0.2 pts | ||
| 3 years | +21.6% | +78.8% | −57.2 pts | +6.7% | +21.4% |
| 5 years | -61.4% | +75.2% | −136.5 pts | -17.3% | +11.9% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Denali Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Update
About Denali Therapeutics
Biological Products, (No Diagnostic Substances)
Denali Therapeutics discovers and develops biotherapeutic medicines designed to treat serious conditions, primarily central nervous system diseases, lysosomal storage disorders, and neurodegenerative illnesses like Alzheimer's and Parkinson's. The company utilizes its proprietary TransportVehicle platform, an engineering approach that leverages receptor-mediated pathways to transport large molecules such as enzymes, oligonucleotides, and antibodies across the blood-brain barrier. Its pipeline includes enzyme replacement therapies such as tividenofusp alfa for Hunter syndrome and DNL126 for Sanfilippo syndrome type A, alongside programs targeting tau and amyloid pathologies in Alzheimer's disease and small-molecule candidates for Parkinson's disease. Denali serves patients with severe genetic and neurodegenerative conditions, collaborating with biopharmaceutical partners like Biogen and Takeda for clinical development and commercialization.
Company profile, executives and historyDenali Therapeutics stock: common questions
What is Denali Therapeutics's stock price?
DNLI closed at $19.73 on Nov 11, 2026, down 0.60% on the day. Over the past 52 weeks it traded between $15.18 and $27.30.
What is Denali Therapeutics's market cap?
Denali Therapeutics was worth $3.15B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is DNLI's P/E ratio?
Denali Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$2.84), so it has no meaningful P/E ratio.
How much revenue does Denali Therapeutics make?
Denali Therapeutics reported revenue of $0 for fiscal 2025.
Does Denali Therapeutics pay a dividend?
No. Denali Therapeutics has not paid a cash dividend over the last twelve months.
When does Denali Therapeutics report earnings next?
Denali Therapeutics is expected to report Q4 FY2026 results on Feb 25, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has DNLI stock performed over the past year?
Including dividends, DNLI returned +12.2% over the past year, against +12.4% for the S&P 500.
How many DNLI shares are sold short?
15M shares were sold short at the latest FINRA report, 9.85% of the float, or 9.9 days of average trading volume.
Who are Denali Therapeutics's competitors?
Companies most similar to Denali Therapeutics by business, industry and size include VYGR, ALEC, PASG, BIIB, MGTX.
See a number that looks wrong?